Showing Results for
- Academic Journals (41)
Search Results
- 41
Academic Journals
- 41
- Search Terms:
- 1From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedLabopharm (Laval, Quebec, Canada) has announced the appointment of Mark D'Souza (right) as CFO. Mr. D'Souza has held senior financial management positions, most recently as vice president, finance at Quebecor Media, and...
- 2From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Jeffrey L Fox [1] August proved a cruel month for biotech companies pursuing plant-made products (PMPs) such as pharmaceuticals and industrial proteins. On August 10, a federal district judge in Hawaii ruled...
- 3From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Hyun Lee [1]; David Zahra [1, 2]; Alexis Vogelzang [1, 2]; Rebecca Newton [1]; Jenny Thatcher [1]; Annie Quan [1]; Trina So [1]; Jörg Zwirner [3]; Frank Koentgen [4]; Søren B Padkjaer [5]; Fabienne Mackay...
- 4From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedThe licensing season is upon us, not that it ever really goes away. Europe's annual cycle of one-to-one meetings, open-house presentations and bioethanolic soirées begins this month with Techvision's BioPartnering...
- 5From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Hepeng Jia [1] A new five-year guideline for the drug industry issued by China's powerful National Development and Reform Commission (NDRC) has given high priority to the development of biotechs and linked...
- 6From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): John Chester; Anja Ruchatz; Michael Gough; Marka Crittenden; Heung Chong; François Loïc-Cosset; Rosa Maria Diaz; Kevin Harrington; Luis Alvarez-Vallina; Richard Vile Nat. Biotechnol. 20, 256-263 (2002);...
- 7From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedChina updates bioethics regulations China will soon release new ethics regulations to cover all aspects of human-related medical research--including preclinical stages--according to remarks made by Yanfei Liu,...
- 8From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Gary Walsh (corresponding author) [1]; Roy Jefferis [2] An understanding of human complexity requires knowing not only the total number of genes but the proteome that is generated through differential...
- 9From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedThe EU's Environment Commissioner Stavros Dimas and long-time biotech critic Jeremy Rifkin of the Foundation on Economic Trends share some common sentiments. They both are passionate about the environment. They both...
- 10From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Leroy Cronin [1]; Natalio Krasnogor [2]; Benjamin G Davis [3]; Cameron Alexander [4]; Neil Robertson [5]; Joachim H G Steinke [6]; Sven L M Schroeder [7]; Andrei N Khlobystov [8]; Geoff Cooper [1]; Paul M...
- 11From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Sean A Beausoleil [1]; Judit Villén [1]; Scott A Gerber [2]; John Rush [3]; Steven P Gygi (corresponding author) [1] Data analysis and interpretation remain major logistical challenges when attempting to...
- 12From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Basant Sharma [1]; Mary H. Ryan [2]; Katia Boven [3] To the editor: In their letter of correspondence "Eprex-associated pure red cell aplasia and leachates" in the June issue (Nat. Biotechnol. 24, 613-614,...
- 13From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Yi Wang [1] As one of the most potent mediators of inflammation, the complement component C5a is a promising target for anti-inflammatory drugs. However, a drawback of using animal models to develop...
- 14From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Kenichi Miharada [1, 2]; Takashi Hiroyama [1]; Kazuhiro Sudo [1]; Toshiro Nagasawa [2]; Yukio Nakamura (corresponding author) [1] Erythroblast enucleation is thought to be largely dependent on signals...
- 15From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Alexander J Stein [1]; H.P.S. Sachdev [2]; Matin Qaim [1] To the editor A News & Views article by Michael Grusak in last year's April issue (Nat. Biotechnol. 23, 429-430, 2005) highlighted the...
- 16From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedGM products will continue to be marginalized in Europe as long as industry remains silent. Organic baby spinach: could anything be more wholesome? According to the website of Earthbound Farm, the largest US grower of...
- 17From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Yuan Qi; Alex Rolfe; Kenzie D MacIsaac; Georg K Gerber; Dmitry Pokholok; Julia Zeitlinger; Timothy Danford; Robin D Dowell; Ernest Fraenkel; Tommi S Jaakkola; Richard A Young; David K Gifford Nat....
- 18From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedIn biological networks, any manifestations of behaviors substantially 'deviant' from the predictions of continuous-deterministic classical chemical kinetics (CCK) are typically ascribed to systems with complex dynamics...
- 19From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Anthony Michael [1] Merely hearing the words "inequitable conduct" would make any person think of some type of egregious act. The term has such a negative connotation that a company accused of patent...
- 20From: Nature Biotechnology. (Vol. 24, Issue 10) Peer-ReviewedAuthor(s): Tom Jacobs [1] When a biotech company succeeds, it can find more cash in the bank than needed for research and development. It may decide to buy back, or repurchase, its own shares. A buyback is neither...